Sanofi reserves up to $2.7B a year for bolt-ons; Alnylam earns $7M milestone from Genzyme;

@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotechFiercePharma and FierceMedicalDevices! | Follow @FierceBiotech

@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce

@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce

@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce

> Faced with falling sales, Sanofi ($SNY) CEO Chris Viehbacher has vowed to invest up to about $2.7 billion a year in new acquisitions. Top fields of interest: diabetes, vaccines, animal health and rare disease. Story

> Cambridge, MA-based Alnylam ($ALNY) is picking up a $7 million milestone from Genzyme for its work on the ATTR drug patisiran. Story

> Progenics ($PGNX) says it will resume a Phase IIb study of Azedra, a rare endocrine tumor drug. Release

Medical Device News

@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev

@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce

> Under Icahn's pressure, Hologic's M&A prospects heat up. Story

> Key piece of Roche, Novo Nordisk diabetes device deal nears EU approval. Article

> Sorin CE nails CE mark for extra-large size of sutureless aortic valve. Item

Pharma News

@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma

@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce

@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce

> 2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A. Report

> Who leaked the scary Copaxone numbers? Teva aims to find out. Story

> J&J's newly approved Olysio to rival Merck and Vertex entries in hep C market. Item

CRO News

> Indian CROs leap into U.S. with joint venture. News

> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More

> ResearchDx reaches into India for contract diagnostics work. News

> Covance taps NeoGenomics for cancer trial diagnostics. Article

> Vietnam taps Quintiles to up its stake in global trials. Story

Biotech IT News

> Google begins hiring team to lead Calico. More

> Life sciences IT execs plan business intelligence spending blitz. News

> Lilly, Novartis and Pfizer sign up to improve ClinicalTrials.gov. Story

> Report finds inexcusable failings in government cybersecurity. Piece

> Novartis looks to data management vendors to slash costs. Article

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.